SecBot SecBot
8-K ·Filed Sep 9, 2026

XERS

Xeris Biopharma Holdings, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed2mo ago SEC0001867096-26-000077
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

This is a significant pipeline catalyst update for a mid-cap biotech. The Phase 3 initiation by year-end and the $1-3B peak revenue estimate provide a clear long-term value thesis. Traders should watch for Cornerstone enrollment updates and potential partnership or financing announcements as the company funds the program itself.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$7.71
T+0 close · Sep 9, 2026 · via day close
Latest settled
+31.13%
T+20 · $10.11 · next T+60 in 16d
Vs SPY
+29.18%
α at T+20
Latest observation
+128.16%
T+46 · FF3 residual α
  1. T+0 · Sep 9 $7.71entry
  2. T+1 · 2mo ago −0.52%α +0.08% · $7.67
  3. T+5 · 2mo ago +0.91%α +1.56% · $7.78
  4. T+20 · 6w ago +31.13%α +29.18% · $10.11
  5. T+48 · todayOpen
  6. T+60 · in 16d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xeris Biopharma hosted a program overview webinar detailing its comprehensive development plan for XP-8121, an investigational once-weekly subcutaneous levothyroxine for hypothyroidism. The company confirmed the Phase 3 Cornerstone registrational study is on track to initiate by year-end 2026 with topline data expected in late 2028, and potential FDA approval and launch anticipated in 2030. Management guided for XP-8121 peak net revenue potential of $1 billion to $3 billion, but this filing contains no actual financial results or new clinical data, it is a forward-looking pipeline update.

Key Facts

  • Phase 3 Cornerstone study on track to initiate by year-end 2026; topline results expected late 2028.
  • Potential FDA approval and commercial launch anticipated in 2030.
  • XP-8121 peak net revenue potential estimated at $1 billion to $3 billion.
  • Cornerstone trial designed with 500 patients across >50 U.S. sites, 15% non-inferiority margin, >90% power.
  • IP coverage through at least 2043 for compositions of matter and methods of use.
  • Company targeting ~$750M total revenue from existing commercial portfolio by 2030.

Financial Impact

XP-8121 peak net revenue potential estimated at $1 billion to $3 billion; company targeting ~$750M total revenue from existing commercial portfolio by 2030

revenue

Risk Factors

  • Clinical trial risk, Phase 3 may fail to meet primary endpoint or show non-inferiority.
  • Regulatory risk, FDA may require additional trials or data beyond Cornerstone.
  • Commercial risk, peak revenue estimates are forward-looking and may not materialize.
  • Financing risk, self-funded program may require dilutive capital raises before 2030 launch.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001867096-26-000077
Exhibit: exh991xp-8121rddaypresen.htm0001867096-26-000077
Exhibit: exh992xp-8121event.htm0001867096-26-000077
Document: 0001867096-26-000077-index-headers.html0001867096-26-000077
Document: 0001867096-26-000077-index.html0001867096-26-000077
Document: 0001867096-26-000077.txt0001867096-26-000077

US Market Status

Market Closed · Opens in 5h 53m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 9, 2026